{"id":"NCT00891371","sponsor":"Ipsen","briefTitle":"Lanreotide Autogel in the Symptomatic Treatment of Refractory Diarrhea","officialTitle":"A Phase II-III, Multicentre, Prospective, Exploratory, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120mg in the Symptomatic Treatment of Patients With Refractory Diarrhea","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2009-07","primaryCompletion":"2012-08","completion":"2013-08","firstPosted":"2009-05-01","resultsPosted":"2015-09-29","lastUpdate":"2019-01-15"},"enrollment":42,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diarrhea"],"interventions":[{"type":"DRUG","name":"lanreotide (Autogel formulation)","otherNames":[]}],"arms":[{"label":"lanreotide (Autogel formulation) Autogel 120mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study, is to assess the effect of lanreotide Autogel 120mg on stool frequency in subjects with refractory diarrhea at day 28 (mean of last 7 days) compared to baseline.","primaryOutcome":{"measure":"Percentage of Patients Having Minimum Reduction of 50% or Normalization (â‰¤3 Stools/24hours) in the Mean Number of Stools (Mean of Last 7 Days)","timeFrame":"Day 28","effectByArm":[{"arm":"Lanreotide Autogel 120 mg","deltaMin":44.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":4},"locations":{"siteCount":11,"countries":["Belgium"]},"refs":{"pmids":["27423779"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":36},"commonTop":["Abdominal pain","Nausea","Fatigue","Headache","Injection site nodule"]}}